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J. Matthew Mahoney1,2* for the Alzheimer’s Disease Neuroimaging Initiative†
1 Department of Neurological Sciences, University of Vermont, Burlington, VT, United States, 2 The Jackson Laboratory, Bar
Harbor, ME, United States
Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder. Since the advent of
the genome-wide association study (GWAS) we have come to understand much about
the genes involved in AD heritability and pathophysiology. Large case-control meta-
GWAS studies have increased our ability to prioritize weaker effect alleles, while the
recent development of network-based functional prediction has provided a mechanism
by which we can use machine learning to reprioritize GWAS hits in the functional
context of relevant brain tissues like the hippocampus and amygdala. In parallel
with these developments, groups like the Alzheimer’s Disease Neuroimaging Initiative
(ADNI) have compiled rich compendia of AD patient data including genotype and
biomarker information, including derived volume measures for relevant structures like
the hippocampus and the amygdala. In this study we wanted to identify genes involved
in AD-related atrophy of these two structures, which are often critically impaired over
the course of the disease. To do this we developed a combined score prioritization
method which uses the cumulative distribution function of a gene’s functional and
positional score, to prioritize top genes that not only segregate with disease status,
but also with hippocampal and amygdalar atrophy. Our method identified a mix of
genes that had previously been identified in AD GWAS including APOE, TOMM40, and
NECTIN2(PVRL2) and several others that have not been identified in AD genetic studies,
but play integral roles in AD-effected functional pathways including IQSEC1, PFN1, and
PAK2. Our findings support the viability of our novel combined score as a method for
prioritizing region- and even cell-specific AD risk genes.
Keywords: gene prioritization, machine learning, GWAS, Alzheimer’s disease (AD), network-based functional
prediction, Alzheimer’s Disease Neuroimaging Initiative (ADNI)
INTRODUCTION
The central goal of genome-wide association studies (GWAS) in Alzheimer’s disease (AD) is to
identify novel candidate genes influencing risk for developing AD. Like other complex disorders,
AD has highly polygenic risk, where hundreds or even thousands of small-effect alleles modify
the probability of developing AD (Lee et al., 2013; Carmona et al., 2018). Fundamentally, this
genetic complexity arises from the underlying biological complexity of AD, where all the major
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cell types of the brain and multiple highly differentiated brain
structures have established roles in pathogenesis or symptom
severity (Calderon-Garcidueñas and Duyckaerts, 2017; Jaroudi
et al., 2017). To fully capture this biological complexity for
genetic mapping, the international community has undertaken
multiple strategies, including case-control GWAS and imaging
GWAS, that capture distinct components of the genetic risk
for AD. In particular, case-control GWAS is well powered to
detect risk alleles but cannot ascribe these effects to specific brain
pathologies. On the other hand, imaging GWAS can localize
the effect of alleles, but these studies have limited sample size
and, therefore, limited statistical power. In this study, we apply a
network-based gene reprioritization (NGR) strategy that leverages
mature functional prioritization methods to integrate AD risk-
gene networks from case-control GWAS with imaging GWAS
data to predict genes that specifically influence hippocampal and
amygdalar atrophy.
The spectrum of AD risk alleles is well studied, particularly
in European populations (Hu et al., 2017; Solomon et al., 2018;
Jansen et al., 2019; Rajan et al., 2019; Andrews et al., 2020). Using
gold-standard cognitive exams that provide robust premortem
diagnoses of AD, modern case-control GWAS are powered to
detect small-effect alleles using large cohorts. These efforts have
culminated most recently in a meta-analysis of AD GWAS
assessing the effect of 9,862,738 SNPs in 71,880 cases and 383,378
controls (Jansen et al., 2019). With such large-scale studies, it
has been possible to detect 2,357 variants and 29 genes with
genome-level significant associations to AD (Jansen et al., 2019).
However, increasing population size has diminishing marginal
returns. Newly resolved effects are ever weaker. Moreover, the
functional role of these alleles cannot be localized to any of the
relevant cellular or regional drivers of AD pathology based on
case-control status alone. Nevertheless, with a valid AD diagnosis
as an endpoint, the alleles mapped in case-control GWAS can be
confidently attributed to AD risk.
As an alternative to large case-control studies, the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) uses structural
magnetic resonance imaging (MRI) as a phenotype for GWAS
(Wyman et al., 2013). In contrast to cognitive exams, which
measure the complex emergent functions of distributed neural
circuits, neuroimaging localizes particular structural pathologies.
In principle, alleles that have a small overall effect on disease
risk could have a comparatively stronger effect on critical
pathologies, including hippocampal and amygdalar atrophy, that
mediate the genetic risk factors for developing AD. However,
MRI is expensive and time-consuming, so the ADNI sample
size is limited to the thousands, not hundreds of thousands, of
subjects. To date, 2272 patients have been recruited, a subset of
556 of which have both imaging and genotype data (ADNI-1
cohort) (Weiner et al., 2015). This dramatically limits statistical
power relative to case-control GWAS. Moreover, while some
longitudinal data have been gathered (Bhagwat et al., 2018), it
is currently impossible to dissociate background developmental
differences in brain structures from pathogenic changes due
to AD. Thus, for example, alleles influencing the growth of
the hippocampus cannot be distinguished from alleles that
exacerbate hippocampal atrophy.
To leverage the independent strengths of case-control and
imaging GWAS, we performed an integrative analysis. Using
NGR with the well-powered case-control meta-GWAS (Jansen
et al., 2019), we identified hippocampus- and amygdala-specific
functional networks that were enriched for AD risk genes. We
then used a novel approach to combine these functional results
with imaging GWAS results for low hippocampal and amygdalar
volume in patients with AD. By combining AD specificity from
NGR with genetic influences on low hippocampal and amygdalar
volume, we can prioritize high-confidence genes for AD-induced
hippocampal and amygdalar atrophy.
The key insight to NGR is that the tail of low p-values
from a GWAS is typically highly enriched for genes in disease-
relevant biological processes, independent of whether most of
those genes achieve genome-wide significance (Greene et al.,
2015). For any choice of statistical cutoff there is a tradeoff
between (a priori unknown) false positives and false negatives. In
particular, genome-wide significance is a conservative threshold
that has many false negatives. With a more liberal threshold, one
captures more true positives at the cost of more false positives,
with no way to discriminate one from the other using GWAS
data alone. In order to distinguish likely true positives from
false positives, NGR augments the GWAS statistical signals with
functional gene-gene interactions. The essential idea of NGR is
that true positive genes, by virtue of being functionally related to
the disease, are likely to be functionally related to each other. By
identifying subnetworks that are enriched for interactions among
nominally significant GWAS genes, we can distinguish the likely
true positives from spurious associations. Several approaches to
NGR have been recently developed, including strategies based on
support vector machines (SVM) (Greene et al., 2015), network
diffusion (Li and Li, 2012), and Bayesian data integration (Wu
et al., 2017). All methods return a functional score for every gene
in the genome (a reprioritization) that measures how strongly
each gene interacts with the nominally significant GWAS hits.
Using NGR, many groups have shown significant improvements
in disease gene prediction (Greene et al., 2015; Wu et al., 2017),
including in AD (Song et al., 2016; Yao et al., 2017).
In this study, following Guan et al. (2010), we used an
ensemble of SVMs to reprioritize AD risk genes from case-
control GWAS using hippocampus- and amygdala-specific
functional networks. We then integrated these tissue-specific
functional scores with imaging GWAS p-values for hippocampal
and amygdalar volume. Using a combined score based on
the joint cumulative density function of functional scores
and imaging GWAS p-values, we prioritized candidate
genes for hippocampal and amygdalar atrophy in AD




We used two distinct GWAS data sets and processed them
through separate pipelines (Figure 1). The first data set
is from the ADNI database and includes genotype and
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FIGURE 1 | Workflow overview. Each data stream, and the calculation of the
integrated score, are indicated by the bolded labels. Each section shows how
data (orange ovals) were processed by computational tools (blue rectangles)
to get results (green diamonds). Arrows indicate flow of information through
the pipeline.
structural MRI imaging data1. The ADNI was launched
in 2003 as a public–private partnership, led by Principal
Investigator Michael W. Weiner, MD. The primary goal of
ADNI has been to test whether serial MRI, positron emission
tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure
the progression of mild cognitive impairment (MCI) and
early AD. Identifying novel biomarkers of AD will help
aid clinicians and researchers develop effective treatments
and interventions.
Alzheimer’s Disease Neuroimaging Initiative is the result of
efforts of many co-investigators from a broad range of academic
institutions and private corporations, and subjects have been
recruited from over 50 sites across the United States and Canada.
The initial goal of ADNI was to recruit 800 subjects but ADNI
has been followed by ADNI-GO and ADNI-2. To date these three
protocols, in addition to the ongoing ADNI-3, have recruited
over 2200 adults, ages 55–90, to participate in the research,
consisting of control, non-AD (CN) older individuals, people
with early or late MCI (EMCI or LMCI), and people with
early AD. The follow up duration of each group is specified
in the protocols for ADNI-1, ADNI-2, and ADNI-GO. Subjects
originally recruited for ADNI-1 and ADNI-GO had the option
to be followed in ADNI-2. Thousands of longitudinal imaging
scans (Jack et al., 2008; Jagust et al., 2010), performance on
neuropsychological and clinical assessments (Petersen et al.,
2010) and biological samples (Shaw et al., 2009) were collected at
baseline and at follow-up visits for all or a subset of participants.
Genome-wide genotyping data (Saykin et al., 2010) are available
on the full ADNI sample. For up to-date information, see
www.adni-info.org.
1adni.loni.usc.edu
Freesurfer version 5.1 was used to extract hippocampal
volume and amygdalar volume measures from the 1.5 T baseline
MRI scans of the ADNI-1 participants as described previously
(Risacher et al., 2013). The measurements were retrieved from
the ADNI data archive.
Genotype data of all participants from ADNI-1 were
downloaded, quality controlled, and imputed to get full coverage
beyond the initial 600,000 SNPs available on the Illumina
610Quad platform. Initial QC was performed using PLINK
1.92 (Chang et al., 2015). Genotype data were processed as
follows: (1) Samples missing more than 10% of their genotype
calls were removed (one person removed), (2) SNPs with a
minor allele frequency (MAF) greater than 0.05 were filtered for
samples missing greater than 5% of the genotype calls and those
with an MAF less than 0.05 were filtered for samples missing
greater than 1% of genotype calls (48,026 variants removed),
(3) duplicated samples were removed (14,238 variants removed),
(4) samples that failed Hardy–Weinberg Equilibrium (HWE)
(p < 10−7) were filtered out (434 variants removed). After QC, we
performed genotype imputation using BEAGLE 5.13 (Browning
et al., 2018). Briefly, genotype data were split by chromosome and
each chromosome was mapped onto the appropriate reference
genome (hg37) and imputed to the CEU 1000 Genomes Project
(1000 Genomes Project Consortium et al., 2015) reference panel.
Imputed chromosomes were recombined using PLINK 1.9 and
underwent an additional round of QC following the procedures
listed above (433 variants removed for not meeting HWE).
After imputation, 14,403,717 variants and 683 samples passed
QC. Hippocampal and amygdalar volumes were used as the
phenotypes in two separate GWAS analyses. A total of 556
individuals had both genotyping data and imaging phenotype
data (n = 120 AD, n = 261 MCI, n = 175 CN). Genome scans
were performed using PLINK 1.9 using a linear regression model
with covariates for age, sex, education, and intracranial volume
(ICV), following the GWAS protocol of a recent ADNI study
using a related network-based gene reprioritization approach
(Song et al., 2016).
SNP-level p-values were mapped to gene level p-values using
MAGMA4 (de Leeuw et al., 2015). SNPs were annotated to genes
using the hg37 genetic reference and a 10 kb annotation window
on either side of the gene. The window size was chosen to match
that used for gene mapping the AD meta-GWAS study (Jansen
et al., 2019). Of the 14,403,717 SNPs contained within the ADNI
genotype data, a total of 6,989,349 SNPs mapped to 18,385 genes.
The HV GWAS yielded 338 nominally significant genes and
three genes that reached a Bonferroni–Holm corrected, genome-
wide significant p-value (Supplementary File 1). The AV GWAS
yielded 276 nominally significant genes and 1 gene that reached
a Bonferroni–Holm corrected genome-wide significant p-value
(Supplementary File 2).
The second data set we analyzed was the AD meta-GWAS
study conducted previously (Jansen et al., 2019). In that study,
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AD data from four major studies including the Alzheimer’s
disease working group of the Psychiatric Genomics Consortium
(PGC-ALZ), the International Genomics of Alzheimer’s Project
(IGAP), the Alzheimer’s Disease Sequencing Project (ADSP),
and UK Biobank (UKB). This analysis resulted in 71,880 AD
cases and 383,378 non-AD controls and 9,862,738 SNPs passing
quality control. SNP associations were calculated by regression as
follows:
(1) Logistic regression was used to calculate SNP
association with case control phenotypes from ADSP,
PGC-ALZ, and IGAP.
(2) Linear regression was used to calculate associations for
a continuous phenotype from UKB (calculated as the
number of parents with AD).
(3) Associations were adjusted for sex as well as age. However,
the ADSP study did not use age as a covariate as the study
group was highly enriched for older patients and inclusion
of age as a covariate in that study eliminated true AD
associations (see Methods: Data Analysis in Jansen et al.,
2019).
(4) The first four ancestry principal components (PCs) were
also used to adjust statistical associations. A total of 20
were calculated and more were used if they showed a strong
association with the phenotype.
(5) For UKB 12 PCs, age, sex, genotyping array, and testing
center were all used as covariates.
SNP summary statistics were downloaded from the Center for
Neurogenomics and Cognitive Research website: https://ctg.cncr.
nl/software/summary_statistics. We used MAGMA to compute
gene-level p-values as above. Of the 13,367,299 SNPs contained
within the meta-GWAS summary statistics, 6,536,525 mapped
to a total of 18,456 genes. At a nominal level of significant
(p < 0.01) the meta-GWAS had 735 significant genes, while
a Bonferroni–Holm corrected p-value yielded 28 genome-wide
significant genes (Supplementary File 3).
Network-Based Gene Repositioning
To functionally score every gene in the genome for relevance
to AD, we performed NGR. NGR requires two inputs: a set of
positive examples of disease-associated genes, and a functional
network encoding gene-gene interactions (cf. Greene et al.,
2015). From these data, NGR uses the network to propagate
the “disease-associated” annotation to genes that are well
connected to the disease-associated gene set. In this study, we
used nominally significant AD-GWAS genes (p < 0.01) from
the MAGMA analysis of the meta-GWAS as disease-associated
genes. For functional networks, we used the hippocampus
and amygdala tissue-specific functional networks freely
available for download at HumanBase5 (‘hippocampus_top’
and ‘amygdala_top’) (Wong et al., 2018). Briefly, these networks
were generated using a regularized Bayesian knowledge
integration based on tissue ontology and a combination of
gene expression datasets from the Gene Expression Omnibus
(Barrett et al., 2013) representing 20,868 conditions (Greene
5https://hb.flatironinstitute.org/download
et al., 2015). Each functional network is a weighted network,
where each pair of genes (gi, gj) is linked with a weight, Wgigj ,
encoding the predicted probability that those genes functionally
interact in that tissue. We define a feature vector, fg , for each
gene, g, in the genome as the vector of weights connecting g
to the n AD-GWAS genes, p1, . . . , pn (i.e., positive examples),
fg = [Wgp1 , . . . , Wgpn ].
Using these feature vectors, we trained an ensemble of 100
(linear) SVM classifiers to distinguish between AD-GWAS genes
and the rest of the genes in the genome. Formally, this problem
is an instance of positive-unlabeled (PU) learning (PU), as we
only have positive examples of AD-relevant genes (i.e., GWAS
hits), but the status of all other genes is unknown. In the PU
learning setting, we can treat all unlabeled examples as negatives
for the sake of training the model, with the understanding
that many unlabeled examples are likely AD-associated genes
(Elkan and Noto, 2008). For each of the 100 SVMs, we trained
using all positive examples and a random, balanced set of
unlabeled examples as putative negatives. Each SVM was cross-
validated to optimize its cost hyperparameter, C, over a grid,
as described previously (Tyler et al., 2019). Each model Mi
assigns each gene, gj, a model-based, real-valued prediction
score Mi(gj), where large positive scores correspond to high
confidence that the gene is a positive example and negative scores
correspond to low confidence. To normalize prediction scores
across models prior to aggregation, we computed an unlabeled-
predicted-positive rate (UPPR) for each model, Mi, and gene,
gj, as,
UPPRij =
#{g ∈ Unlabeled | Mi(g) > Mi (gj)}
#{g ∈ Unlabeled} | Mi(g) > Mi(gj)}
+ #{g ∈ Unlabeled | Mi(gj) > Mi (g)}
where ‘#’ denotes the cardinality of a finite set. The UPPR is
the PU-learning equivalent of the false positive rate, where lower
values indicate higher confidence that a gene is functionally
associated with the AD GWAS genes. We averaged UPPR over















The functional score ranges from zero to infinity, with higher
values indicating greater confidence. Models were trained using
the e1071 R package (Meyer et al., 2019).
Integrating Functional and Positional
Scores
To integrate functional scores for AD-specificity with imaging
GWAS p-values, we computed a novel combined score based
on the empirical joint cumulative density function (CDF) of
the two scores. Specifically, every gene, g, had a functional
score FS(g), and a positional score PS(g) = –log10(pg),
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where pg is the MAGMA p-value for g in the imaging
GWAS. To quantify how highly ranked a gene, gj, is
along both measures simultaneously, we used the value

























where N is the number of genes in the genome. Note that
this is equivalent to the probabilistic definition using the
empirical joint distribution of the two scores. Thus, the combined
score represents the probability that a randomly chosen gene
in the genome will score lower on both measures than
gj.
Functional Enrichment Analysis
To compare the functional enrichments of ADNI imaging
genetics p-values versus the combined scores, we used the g:GOSt
tool in the gprofiler2 R package to identify significantly enriched
Gene Ontology terms (Kolberg et al., 2020). Specifically, we
ranked all genes by either p-value or combined score and tested
the significance of all Gene Ontology Biological Process (GO:BP)
terms (Ashburner et al., 2000; Carbon et al., 2018). We then
summarized the enriched term lists into high-level annotations
using the REVIGO online ontology analysis tool (Supek et al.,
2011). Finally, we plotted high-level annotations as pie charts
using ggplot2 (Wickham, 2016).
Modularity and Gene Enrichment
Analysis of Functional Networks
To visualize and interpret the outputs of our SVM predictions,
we plotted sub-networks of high-ranking genes and performed
enrichment analyses of network modules. For both the
hippocampal and amygdalar networks, we extracted the
sub-networks of genes with functional scores greater than
two (i.e., average UPPR < 0.01). We visualized these sub-
networks using force-directed layout (Jacomy et al., 2014) in
Gephi6 (Bastian et al., 2009). We identified modules in this
sub-network using maximum modularity as implemented
in Gephi (Blondel et al., 2008). The list of genes in each
module was then sorted by functional score and input to
g:GOSt (Raudvere et al., 2019), resulting in significantly
enriched Gene Ontology (Ashburner et al., 2000; Carbon
et al., 2018), KEGG (Kanehisa and Goto, 2000), and
Reactome (Jassal et al., 2019) terms. Network modules
were annotated by manually curating a set of representative
functional terms, and the full output g:GOSt can be viewed in
Supplementary Files 4, 5.
Code Availability
To ensure rigor and reproducibility of our results, all analysis





Volume, and AD Diagnosis Captured
Distinct Genetic Signals
The ADNI-1 dataset contains measures of hippocampal volume
(HV) and amygdalar volume (AV) of patients and controls
derived from structural MRI, as well as multiple relevant
covariates: sex, age, educational attainment, and total ICV. Both
of these brain volume measures correlated strongly with a
patient’s clinical cognitive status (Figure 2A). Regional volumes
were highest in control, non-AD (CN) subjects, lower in late mild
cognitive impairment (LMCI) subjects, and lowest in patients
with AD (Figure 2A). While there was overlap between the
subgroups in HV and AV, the average size of each structure was
significantly different between each clinical group (Figure 2A),
as has been previously shown in prior ADNI work (Schuff et al.,
2009; Whitwell et al., 2012).
The hippocampus and amygdala take part in overlapping
limbic system neural pathways and are physically close to one
another in the temporal lobe, suggesting that atrophy of each
of these structures in AD could be highly correlated (Cavedo
et al., 2011; Wang et al., 2016). To assess this, we corrected
HV and AV for diagnosis at baseline, ICV, years of education,
age, and sex using a linear model and computed the correlation
of the residuals (Figure 2B). The residuals were significantly
correlated (R2 = 0.41, p = 3.2e-66), indicating a significant, but
moderate, correlation between the sizes of the two structures. The
moderate correlation indicates that there are likely overlapping
processes driving the size of these structures, but also biological
processes that are unique to each. It is interesting to note that,
after controlling for covariates, the distributions of HV and
AV are unimodal and do not have any obvious subgroupings.
Thus, for the remainder of the study, we treated HV and AV as
quantitative traits.
To identify genetic drivers HV and AV in patients with
AD, we used PLINK 1.9 (Chang et al., 2015) to statistically
associate SNPs to HV and AV, and used MAGMA (de Leeuw
et al., 2015) to integrate SNP-level association to gene-level
associations (Figure 1). Overall, three genes—APOC1, TOMM40,
and APOE—were significant after correcting for multiple
comparisons for HV, and one gene—APOC1—was significant
for AV. Furthermore, 338 and 276 genes were nominally
significant at the p = 0.01 level for HV and AV, respectively.
The top-ranked genes by p-value for both HV and AV were
APOC1, TOMM40, and APOE, which all have well-established
associations to AD (Zhou et al., 2014; Chiba-Falek et al., 2018;
Zhao et al., 2018). Examining the nominally significant genes, we
found that HV and AV independently associated with a unique
subset of genes (Figure 2C). For example, the gene GRIN2B,
which plays a role in brain development and is a candidate
gene for temporal lobe epilepsy and autism spectrum disorder
due to its effects on the hippocampus (Parrish et al., 2013;
Varghese et al., 2017), was nominally significant for HV but
not AV. Conversely, the gene EDN1, which is a candidate gene
antagonist for multiple system atrophy (Gu et al., 2018), was
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FIGURE 2 | Data processing and comparison of hippocampal and amygdalar volume GWAS and meta-GWAS summary statistics. (A) We calculated the correlation
between each of the three clinical diagnoses for ADNI-1 and the respective tissue volume measures. All three diagnoses showed significant (p < 2e-16) differences
in average volume size across tissues. (B) Linear models predicting HV and AV were calculated to determine the correlation in size of the two structures. There was a
significant, moderate correlation (R2 = 0.41, p = 3.6e-66) between the volumes of the two structures controlling for diagnosis at baseline, education, sex, ICV, and
age. (C) Comparison of p-value distributions for the two GWAS volume measures. Dotted lines indicate a nominal significance cutoff of 0.01. (D,E) Comparison of
p-value distributions between the meta-GWAS data and the respective volume GWAS data. Genes with log transformed p-values greater than 20 were transformed
to 20. Black dotted lines indicate a nominal significance cutoff of 0.01.
nominally significant for AV but not HV. These results suggest
that large-effect genes may have pleiotropic effects on HV and
AV, but also that separate pathways may be driving atrophy in
particular structures.
The virtue of endophenotypic measures such as HV and AV
is they can potentially resolve biologically specific components
of a disease that are otherwise too convoluted with other
disease mechanisms when considering disease status alone.
However, because the ADNI data are cross-sectional, it is not
clear a priori whether genetic effects on HV or AV relate to
genetic differences in brain developmental or to AD-induced
atrophy. To assess the concordance between gene associations
for HV and AV associations with AD risk per se, we compared
gene-level p-values for HV and AV to corresponding p-values
from the AD meta-GWAS study recently published (Jansen
et al., 2019) (Figures 2D,E). The Jansen et al. (2019) study
is the largest AD meta-GWAS to date, and provides the
most robust data set to identify any HV- or AV-specific hits
influencing AD risk. Like the comparison between HV and
AV p-values, the meta-GWAS shares several genome-wide
significant genes with HV and AV (Figures 2D,E). Furthermore,
the meta-GWAS shares some nominally significant genes with
imaging GWAS, for example, ENAH with AV and PICALM
for HV (Figures 2D,E). These overlapping hits, at a nominal
significance level, suggest that at least some of the variation
in HV and AV is potentially driven by factors influencing
genetic AD risk.
NGR Identified Distinct Hippocampal and
Amygdalar Functional Gene Networks
Connecting AD Risk Genes
As major components of AD pathology, genetic risk factors for
AD-induced hippocampal and amygdalar atrophy are expected to
be a subset of all AD risk factors. However, differences in sample
size (i.e., statistical power) and study population between the
case-control and imaging GWAS limit our ability to detect these
overlapping associations. Nevertheless, we expect that, beyond
specific shared gene associations between HV and AV and disease
risk, risk genes for imaging endophenotypes should lie in AD
risk gene pathways. To identify the hippocampal and amygdalar
pathways involved in AD pathogenesis, we performed NGR
using hippocampus- and amygdala-specific functional genomic
networks (Wong et al., 2018) to rank every gene in the genome by
how well they connect to AD-GWAS genes. Briefly, we trained an
ensemble of SVM classifiers to distinguish between AD-GWAS
genes and the rest of the genome using connection weights to
AD-GWAS genes in the tissue networks as features (see section
“Materials and Methods”). The output of this analysis was a
ranked list of genes with each gene receiving a functional score
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(formally, the negative logarithm of the unlabeled-predicted-
positive rate) that quantifies how well connected a gene is to
AD-GWAS genes. As positive examples we used all genes that
reached a nominal level of significance (p = 0.01) in the meta-
GWAS dataset (n = 735 genes). The remaining genes were
treated as unlabeled.
To aid the interpretation of top functional hits, we visualized
the sub-networks of genes that had functional scores greater
than 2 for the hippocampus and amygdala networks. We
performed modularity analysis in Gephi (Bastian et al., 2009)
and identified four modules in both sub-networks (Figure 3).
We assigned functional annotations to the genes from each
network module using g:GOSt (Raudvere et al., 2019). While
the number of modules were the same for both tissue sub-
networks, the functional annotations underscored distinct
pathways. The hippocampus sub-network modules were
enriched for genes taking part in endothelial cell migration
(GO:0043542), regulation of cell adhesion (GO:0030155),
Rho/RAS mediated GTPase activity (GO:0007266, GO:0046578),
and regulation of macroautophagy (GO:0016241) (Figure 3A).
The amygdala sub-network modules were enriched for genes
involved in regulation of the ERK signaling cascade and protein
ubiquitination (GO:0070372, GO:0030433), cytoskeletal and
organelle organization (GO:0051493, GO:0033043), chromatin
and chromosome organization (GO:0006325), and apoptotic
signaling and cell death (GO:2001233, GO:0010941) (Figure 3B).
These enrichments covered a diverse range of processes,
some of which overlapped between tissues (e.g., regulation
of macroautophagy and apoptotic signaling and cell death),
while others appeared to be tissue-specific (e.g., endothelial cell
migration in the hippocampus).
Integration of Functional Scores With
Imaging GWAS p-Values Predicted Risk
Genes for AD-Induced Hippocampal and
Amygdalar Atrophy
The HV and AV measurements are cross-sectional and cannot
resolve whether a genetic association is due to AD-driven atrophy
or a genetically encoded difference in brain development. Thus,
the genes that associate with HV and AV need not necessarily
associate with disease status. In order to identify genes that
were simultaneously associated with HV or AV and functionally
connected to AD disease risk, we computed a combined score
using the joint cumulative density function of the imaging
GWAS p-values and the functional scores from NGR. The
resulting scores ranged continuously from zero to one, with
values closer to one indicating a higher rank on both genetic
and functional metrics. Plotting the functional score vs. the
negative logarithm of the imaging GWAS p-value with a color
gradient indicating each gene’s combined score, we see that some
genes in the upper-right quadrant of the point cloud scored
FIGURE 3 | Analysis of top functional subnetworks. The functional subnetwork of genes with a functional scores greater than 2 were extracted from both tissue
networks, run through a modularity algorithm, and the modules were functionally annotated using functional enrichment analysis by g:OSt. Several of the top hit
genes from the combined ranking appeared in a diverse array of functional classifications. Each gene is colored by the functional module in which it is a member.
Network edges were filtered to only include weights greater than 0.25 for visual clarity. (A) Amygdala sub-network analysis. The top functional sub-network for this
tissue was enriched for genes in pathways that regulate apoptosis and cell death, cytoskeletal and organelle organization and chromosomal organization.
(B) Hippocampus sub-network analysis. This top functional sub-network was enriched for genes involved in immune signaling as well as cell adhesion and ER
regulation.
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FIGURE 4 | Combined score ranking. Points are colored on a gradient by combined score with yellow points scoring highest, and blue points scoring lowest.
(A) The combined score plot for the amygdala tissue. Several of the top ranked genes were involved in the regulation gene transcription (EDF1) or the maintenance
of organelles (PRKCSH, UBE2J2) and integrity of the synapse (PAK2, ENAH). (B) The combined score plot for the hippocampus tissue. Several genes were involved
in processes required for the maintenance of the synapse (PFN1, IQSEC1) regulation of gene transcription (HDAC3) and proper ER regulation (PRKCSH, MOGS).
better than 95% of the genes in the genome on both axes
(Figures 4A,B).
The purpose of the combined score was to prioritize AD-
specific genes and distinguish them from genes influencing HV
and AV through developmental pathways. To establish a specific
enrichment for AD-relevant pathways, we compared functional
enrichments between ranking genes by p-value (ascending)
and by combined score (descending). To summarize the large
lists of enriched terms, we used REVIGO to compress the
enrichments into representative high-level terms (Supek et al.,
2011). For the hippocampus and amygdala (Figure 5), the p-value
analyses revealed an enrichment for genes involved in cholesterol
metabolism and cell adhesion. On the other hand, the combined
score in the hippocampus was enriched for terms involved in
the regulation of the immune response and cellular stress related
to the endoplasmic reticulum (ER). Similarly, for the amygdala,
the combined score was enriched for pathways involved in
ER stress and neuron growth. These results demonstrate that
the combined score prioritizes genes involved in AD-relevant
functional pathways, distinct from those regulated by APOE (e.g.,
cholesterol metabolism) (Schliebs and Arendt, 2011; Heneka
et al., 2015; Gerakis and Hetz, 2018).
Notably, while the combined score ranked genes involved in
AD-relevant pathways highly, many of the top-10 genes have
not been previously annotated to the disease (Tables 1, 2).
High-scoring hippocampal genes are involved in actin regulation
(PFN1, IQSEC1, PAK2), protein regulation in the ER (MOGS
and PRKCSH), and transcriptional regulation (HDAC3). Highly
ranked genes in the amygdala are involved in a wide range
of processes, including regulation of proteins in the ER
(PRKCSH and UBE2J2), transcription modification or cell cycle
modulation (KAT5, EDF1, and ZNHIT1), and the maintenance
and development of healthy synapses (SRGAP1 and PAK2). The
top 10 genes in both the hippocampus and amygdala were
distributed throughout the NGR functional networks and were
present in all functional modules (Figure 3).
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FIGURE 5 | Functional enrichment analysis using p-value and combined score. (A) Functional enrichment analysis of amygdala volume GWAS p-value ranking and
combined score rankings. The p-value functional enrichment analysis revealed terms like biological cell adhesion and macromolecular complex remodeling. By
comparison, the functional enrichment analysis for the combined score revealed terms relating to ER stress, neuron projection development, and response to oxygen
levels which are all pathways affected by AD pathophysiology. (B) Functional enrichment analysis of hippocampal volume GWAS p-value ranking and combined
score rankings. The p-value functional enrichment analysis saw similar enrichments as the amygdala p-value functional enrichment analysis. The combined score
functional enrichment analysis on the other hand, saw enrichment of pathways involved in development, ER stress, and immune response regulation.
DISCUSSION
As a complex disease, the genetic risk for AD is distributed over a
wide variety of cellular and molecular pathways. Thus, the genetic
architecture of AD is expected to be dominated by thousands of
small-effect variants that each slightly perturb brain physiology
toward a more AD-susceptible state, rather than a small set of
highly penetrant mutations. Indeed, even the well-studied APOE-
E4 risk allele has an odds ratio of only 11.8 in the Caucasian
population, which is by no means a certainty for any carrier (Jia
et al., 2020). The value of genetic network analysis to the study
of the architecture of complex disease, therefore, is to aggregate
these many small perturbations into a pathway- and process-level
description of the full disease. To this end, our results clearly
implicate common mutations in many genes as perturbations
of pathways that react to the aberrant accumulation of Aβ in
the brain (Figure 6; discussed below). Far from being statistical
noise, genes with nominally significant p-value from the imaging
GWAS are enriched for AD-specific biology. Interestingly, the
gene-level p-values largely did not replicate between imaging
GWAS and the case-control meta-GWAS. It was only after
identifying the relevant tissue-specific functional sub-networks
with NGR that we could resolve the likely AD-specific genes
for HV and AV. Validating any of these high-ranking genes
as specifically influencing hippocampal or amygdalar atrophy is
beyond the scope of this study, but many top hits have strong
connections to well-established AD biology.
The pathognomonic signature of AD is the aggregation of
amyloid β (Aβ) peptide into amyloid plaques in the brain.
Beyond aggregating into plaques, however, Aβ is associated with
a number of pathological processes, including loss of synaptic
integrity (Rönicke et al., 2011; Parsons and Raymond, 2014;
Wang and Reddy, 2016; Singh et al., 2017; Kang and Woo, 2019;
Schaeverbeke et al., 2019) and dysregulating neuronal and
astrocytic calcium channels (Yu et al., 2005; Rönicke et al., 2011;
Parsons and Raymond, 2014; Lim et al., 2016; Wang and Reddy,
2016; Verkhratsky et al., 2017; Liu et al., 2019). At the astrocyte,
Aβ has been shown to bind Alpha-7 nicotinic acetylcholine
receptors (α7 nAChRs), causing an influx of calcium to the
astrocyte and glutamate release into the synapse (Pirttimaki et al.,
2013). At the synapse, Aβ has been shown to bind to N-methyl-
D-aspartate receptors (NMDARs) preventing glutamate from
activating the channel to allow an influx of calcium ions (Liu
et al., 2019). Loss of current through NMDARs drives depression
of synaptic strength at that synapse, as lower levels of calcium
initially drive the endocytosis of α-amino-3-hydroxy-5-methyl-4-
isoxasolepropionic acid receptors (AMPARs) and later NMDARs
in the postsynaptic neuron (Tigaret et al., 2006; Yu et al., 2010).
Loss of synaptic efficacy is a critical signal for synaptic pruning
(Lüscher and Malenka, 2012), and an accumulated loss of
synapses is one possible mechanism for loss of network function.
Beyond synaptic pruning, Aβ is associated with a loss of synaptic
integrity, where the neurotransmitters, such as glutamate, can
leak out of the synapse and activate extra-synaptic receptors
(Hardingham and Bading, 2010; Parsons and Raymond, 2014).
It has been hypothesized that the high level of glutamate release
by astrocytes leads to an increase in extra-synaptic glutamate
signaling and excitotoxicity (Sattler et al., 2000; Hardingham and
Bading, 2010; Parsons and Raymond, 2014; Wang and Reddy,
2016), which is hypothesized to both induce ER stress (Sokka
et al., 2007; Concannon et al., 2008) and activate pro-apoptotic
pathways (Hardingham et al., 2002), while antagonizing pro-
survival pathways, particularly brain-derived neurotrophic factor
(BDNF) signaling, leading to neuron death (Hardingham et al.,
2002; Hardingham and Bading, 2010; Parsons and Raymond,
2014; Wang and Reddy, 2016). Thus, the accumulation of Aβ
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TABLE 1 | Brief descriptions of the top genes according to the combined score for the hippocampus.
Gene Functional Score p-value Role (with PMID)
PFN1 0.00148 1.56E-03 Increased actin depolymerization in hippocampus of APP/PS1 mice indicates impaired
synaptic plasticity (PMID: 31472195). Actin remodeling mediated by SGK1, a gene
involved in spatial memory formation and consolidation (PMID: 31981651). Critical for
proper PNS myelination, organization, and development (PMID: 24598164).
HDAC3 0.00549 2.44E-03 Nuclear HDAC3 is significantly increased in the hippocampus of 6- and 9-month-old
APP/PS1 mice compared with age-matched wild-type C57BL/6 mice. Inhibition of
HDAC3 in the hippocampus attenuated spatial memory deficits, and decreased amyloid
plaque load and ABeta levels. Dendiritic spine density increased while microglial
activation alleviated after HDAC3 inhibition. Over expression led to an increase in
hipppocampal feels of Abeta, activation of microglia, and decreased dendritic spine
density (PMID: 28771976).
PRKCSH 0.00249 6.06E-03 Colocalizes with IP3Rs which mediate calcium release from the ER, specifically in
hippocampal neurons. Additionally, PRKCSH enhances IP3-induced calcium release
and has been found to regulate ATP-induced CA2(+ (PMID: 18990696).
APOE (29107063) 0.0130 1.78E-12 Lipid transporter that binds to cell-surface receptors to aid in cholesterol transport and
membrane homeostasis. It is present in a broad range of functional pathways within the
CNS including synaptic plasticity, mitochondrial function, and neuroinflammation. Its
epsilon 4 allele is one of the biggest risk factors for AD (PMID: 28434655).
MOGS 0.00581 7.21E-03 Located in the lumen of the ER where it performs N-linked glycosylation. Several
mutations within the gene can lead to congenital diseases of glycosylation which can
lead to major structural malformations within the brain, liver, lungs, and many other
higher-order tissues and organs (PMID: 30587846).
NECTIN2 (29107063) 0.0141 8.12E-07 Also known as PVRL2, this gene is a component protein of adherens junctions between
cells. Has wide ranging roles in cell signaling to natural killer cells to leukocyte transport
in endothelial cells (PMID: 28062492).
PICALM (19734902) 0.0109 3.52E-03 Involved in clathrin assembly. Two SNPs 5′ to the gene are associated with Reduced
LOAD Risk (PMID: 19734902; 24162737; 19734903), but their functions have not yet
been determined. It colocalizes with APP and over-expression of PICALM in vivo
increases plaque deposition in AD transgenic mice (PMID: 22539346). Binds to
autophagosomes, suggesting a role in autophagy mediated Abeta clearance (PMID:
24067654).
NACC2 0.0139 5.19E-04 Transcription repressor within the p53 pathway: inhibits the expression of MDM2 which
stabilizes the expression of p53 an important tumor suppressor (PMID: 22926524).
IQSEC1 0.00974 6.14E-03 Loss of function affects a wide variety of actin-dependent cellular processes, including
AMPA and NMDA receptor trafficking at synapses (PMID: 20547133). Mutations have
led to intellectual disability and developmental delays in those affected (PMID:
31607425).
CYB561 0.00496 1.24E-02 An electron transporter critical for the conversion of dopamine to epinephrine and
norepinephrine. A mutation in this gene, which disrupts the final production of
norepinephrine, has been observed in families with severe orthostatic hypotension
(PMID: 29343526).
Genes in bold have been previously found in AD GWAS. PMIDs from supporting papers are included in parentheses next to bolded gene names.
acts through multiple complex pathways—at the synapse, at the
ER, and through transcriptional regulation—to cause atrophy
of neural tissue. Importantly, our top-ranking genes in both
the hippocampus and the amygdala act in these Aβ-response
pathways.
Multiple High-Ranking Genes Influence
Synaptic Structure Through the
Cytoskeleton
Altered synaptic structure and function are well-established in
AD (Spires-Jones and Knafo, 2012; Pozueta et al., 2013; Chabrier
et al., 2014; Price et al., 2014; Mango et al., 2019; Koller and
Chakrabarty, 2020). The highest-ranking hippocampal gene,
PFN1 (Figure 6A and Table 1), encodes an actin-monomer
binding protein that is known to regulate the cytoskeleton of
neurites (Murk et al., 2012), but has also been shown to support
the highly mobile F-actin in astrocytic projections that surround
synaptic clefts (Schweinhuber et al., 2015). It has been associated
with impaired synaptic plasticity and spatial memory in the
APP/PS1 mouse model of AD (Sun et al., 2019; Lian et al., 2020).
Alterations to the function of PFN1 due to AD risk mutations
could account for alterations in synaptic maintenance, leading
to increased glutamate signaling to extra-synaptic NMDARs.
PFN1 activity is promoted by BDNF, which is hypothesized to be
inhibited by extrasynaptic glutamate signaling, and loss of that
signal could stop proper formation of actin at neurite outgrowths
and potentially in astrocytic processes supporting synaptic clefts
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TABLE 2 | Brief descriptions of the top genes according to the combined score for the amygdala.
Gene Functional Score p-value Role (with PMID)
PRKCSH 0.0293 1.13E-03 Colocalizes with IP3Rs which mediate calcium release from the ER, specifically in
hippocampal neurons. Additionally, PRKCSH enhances IP3-induced calcium release
and has been found to regulate ATP-induced CA2+ (PMID: 18990696).
TOMM40 (29107063) 0.00626 2.66E-11 Mitochondrial membrane protein critical for transport of protein precursors into the
mitochondria and is associated with mitochondrial dysfunction in AD. Further, it has
recently been found to be associated with functional connectivity of brain regions via
fMRI (PMID: 31568198). It is in LD with APOE.
PAK2 0.00508 9.50E-04 Haploinsufficiency of PAK2 has been observed to decrease synapse density, impair LTP,
and drive autism related behaviors in mice (PMID: 30134165). Strong regulator of
cellular senescence and organismal aging through gene-expression and the H3.3
nucleosome assembly (PMID: 31209047).
SRGAP1 0.00308 2.89E-03 A GTPase activator that works with CDC42 to negatively regulate neuronal migration.
Interacts with ROBO1 to inactivate CDC42 (PMID: 11672528).
UBE2J2 0.00771 2.88E-04 Ubiquitination by this protein is a potential mechanism for endoplasmic
reticulum-associated depredation (ERAD) (PMID: 19951915; 25083800).
KAT5 0.00459 4.31E-03 A histone acetyl transferase (HAT) that plays a role in DNA repair and apoptosis as well
as signal transduction. Complexes with the intracellular domain of the cleaved APP
products to form nuclear spheres which seem to have a role in cell-cycle regulation, but
are not well understood (PMID: 27644079).
EDF1 0.00181 8.50E-03 Transcriptional regulator of PPAR-gamma which has a wide array of roles in combatting
AD pathophysiology including amyloid clearance and metabolic regulation (PMID:
22109891, 24838579).
ENAH 0.00740 6.99E-03 Complexes with FE65 and that association may have an effect on APP biogenesis
(PMID: 9407065). Also involved in actin polymerization and cell motility (PMID:
10069337, 10892743).
ZNHIT1 0.00368 1.63E-02 Induces arrest of cell cycle at G1 and CDK6 was strongly down-regulated by Znhit1
through transcriptional repression (PMID: 19501046). CDK6 is unregulated in patients in
AD compared to non-AD controls (PMID: 26766955).
APOE (29107063) 0.0162 7.00E-11 Lipid transporter that binds to cell-surface receptors to aid in cholesterol transport and
membrane homeostasis. It is present in a broad range of functional pathways within the
CNS including synaptic plasticity, mitochondrial function, and neuroinflammation. Its
epsilon 4 allele is one of the biggest risk factors for AD (PMID: 28434655).
Genes in bold have been previously found in AD GWAS. PMIDs from supporting papers are included in parentheses next to bolded gene names.
(Murk et al., 2012; Parsons and Raymond, 2014; Schweinhuber
et al., 2015).
Another high-ranking hippocampal gene was IQSEC1 (also
known as BRAG2), which encodes a guanine nucleotide exchange
factor, ARF-GEF100, that is critical for the proper maintenance
of excitatory synapses through AMPA and NMDA receptor
trafficking, and regulating synaptic long-term depression (Ottis
et al., 2013; Elagabani et al., 2016; Um, 2017; Ansar et al., 2019)
(Figure 6B and Table 1). Loss of function mutations in IQSEC1
have been associated with intellectual disability (Elagabani et al.,
2016) and a biallelic variant mutation has been observed in
two families exhibiting intellectual disability and developmental
delays (Ansar et al., 2019). A recent study in Wistar rats found
that BRAG2 is a member of a small network of proteins that are
dysregulated in response to age-induced changes in proteostasis
(Ottis et al., 2013). Significantly, changes in this protein network
lead to impaired learning and memory performance (Ottis
et al., 2013). Thus, common variants in IQSEC1 could play
a role in synaptic reorganization in response to aging and
Aβ burden in AD.
The highest scoring amygdala gene was PAK2, which supports
actin formation and the promotion of dendritic spine formation
(Bokoch, 2003; Shin et al., 2009; Wang et al., 2018) (Figure 6C
and Table 2). Mutations in PAK2 are associated with other
neurological disorders, including autism spectrum disorder and
a 3q29 microdeletion syndrome with a range of neurological
phenotypes including intellectual disability and autism (Wang
et al., 2018). PAK family proteins have been associated with
impaired dendritic spine formation in in vitro AD models (Ma
et al., 2008), and PAK2 has been shown to be cleaved by caspase
resulting in cell death (Marlin et al., 2011). Recent work has
also shown that LIMK1, a downstream signaling molecule from
PAK2, is involved in a ROCK2 actin regulatory pathway which
mediates Aβ42-induced spine degeneration as well as neuronal
hyperexcitability in hAPP mice (Henderson et al., 2019). PAK2
activity is regulated by the Slit/roundabout (ROBO) signaling
pathway (Dubrac et al., 2016; Xu et al., 2018), which is primarily
involved in modulating axonal guidance and neuronal migration
(Dickson and Gilestro, 2006; Mastick et al., 2010; Slováková et al.,
2012), via the CDC42 GTPase (Wong et al., 2001; Xu et al.,
2018; Huang et al., 2020). Another high-ranking amygdala gene,
SRGAP1, suppresses the activity of PAK2 through the Slit/ROBO
signaling pathway (Dubrac et al., 2016; Xu et al., 2018) (Figure 6C
and Table 2). Slit binds to ROBO and activates the SRGAP1
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FIGURE 6 | Illustration of neuronal and astrocytic pathways implicated in the disease according to the top scoring genes according to our integrated ranking.
(A) Loss of signal from BDNF to PFN1 downregulates the activity of the gene, impairing F-actin structure in the neuron and astrocyte. (B) IQSEC1 mediates AMPAR
and NMDAR receptor internalization. (C) PAK2 activity is partially regulated by the CDC42 GTPase which is activated by binding of the SLIT protein to ROBO at the
membrane. This activity can be interrupted by the activity of SRGAP1 which inhibits ROBO signaling. (D) ENAH can bind to both ROBO and Fe65. When bound to
ROBO it acts to inhibit actin polymerization and motility, but while bound to Fe65 and the AICD the ROBO pathway functions normally, promoting cell motility, and
actin polymerization. (E) PRKCSH co-localizes with IP3Rs increasing calcium current through the channels, increasing cytosolic levels of Ca2+. (F) UBE2J2 and
MOGS are both involved in the proper regulation of intra-ER processes. Impairment of the proper activity of post-translational modification by MOGS could drive
ERAD mediated by ubiquitination by UBE2J2. (G) EDF1 is also a transcriptional regulator for PPAR-gamma. Activation of PPAR-gamma helps to regulate disturbed
metabolic states and A plaque clearance. (H) HDAC3 regulates transcription of many genes that have an effect on Aβ burden, microglial activation, and dendritic
spine density.
protein which triggers the hydrolysis of GTP by the CDC42
GTPase, which attenuates PAK2 activity (Dubrac et al., 2016; Feng
et al., 2016). Thus, common variants that modify the activity of
PAK2 or its upstream regulator, SRGAP1, could lead to alterations
in synaptic morphology and axonal migration, and possibly to
cleaved PAK2 signaling for neuronal death.
A final cytoskeletal protein among the top-rankings genes
was ENAH in the amygdala. The ENAH protein has been found
to form a complex with Fe65, a transcriptional activator and
protein involved in neurite outgrowth and binding partner of
amyloid precursor protein (APP) (Sabo et al., 2001; Li et al., 2018)
(Figure 6D and Table 2). ENAH also binds to ROBO and profilin
(PFN), acting as an inhibitor of motility and regulator of actin
dynamics, respectively (Gertler et al., 1996; Lanier et al., 1999;
Bear et al., 2000; Lanier and Gertler, 2000). Greater association of
ENAH with the Fe65-APP complex supports neurite outgrowth
and motility, whereas binding to ROBO inhibits that activity
(Sabo et al., 2001). Common variants in ENAH, therefore, could
influence synaptic plasticity through its association with the
major AD risk factor APP (Trillaud-Doppia and Boehm, 2018).
PRKCSH Potentially Regulates
Excitotoxicity in AD
Loss of synaptic integrity coupled with impaired glutamate
clearance by astrocytes caused by Aβ leads to high levels of
extracellular glutamate, which binds to NMDARs increasing
intracellular calcium levels (Parsons and Raymond, 2014;
Liu et al., 2019). Under physiological conditions, the ER
and other organelles act as calcium sinks that modulate
intracellular ion levels.
Excitotoxicity occurs when intracellular calcium levels exceed
the buffering capacity of the cell. The only top-ten gene shared
by both tissues, aside from APOE, was PRKCSH (Tables 1, 2),
which encodes the protein kinase C substrate 80K-H (80K-H), a
glucosidase enzyme in the ER. 80K-H is known to colocalize with
the inositol triphosphate receptor (IP3R), an ER-resident calcium
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channel that facilitates calcium currents in the ER (Kawaai et al.,
2009) (Figure 6E). Common variants in PRKCSH could modify
neuronal responses to excitotoxic levels of calcium, potentially
exacerbating tissue atrophy in the hippocampus and amygdala.
ER Stress and Misfolded Protein
Response Genes Could Contribute to
Apoptotic Signaling
Several other high-ranking genes are integral to the proper
folding of proteins in the ER. ER stress occurs when the ability
of the ER to properly fold proteins becomes saturated (Lin et al.,
2007). The hippocampal gene MOGS encodes a glycosylation
enzyme that aids in protein folding (Sadat et al., 2014; Li et al.,
2019) (Figure 6F and Table 1). Common variants in MOGS
could modify the rate at which ER stress occurs and exacerbate
AD-related hippocampal atrophy.
When the ER reaches a critical state of misfolded proteins,
ER-associated degradation (ERAD) can be triggered. ERAD
is a process by which misfolded proteins are ubiquitinated
and then proteolyzed to prevent the misfolded polymers from
causing cellular damage. The amygdalar gene UBE2J2 encodes
a ubiquitin conjugating enzyme that marks misfolded proteins
for degradation (Wang et al., 2009; Glaeser et al., 2018)
(Figure 6F and Table 2). In some cases, ERAD can be triggered
as part of apoptosis, and ubiquitination enzymes, including
UBE2J2, are recruited to ubiquitinate misfolded proteins (Glaeser
et al., 2018). Common variants in UBE2J2 could affect the
misfolded protein response and exacerbate cellular damage due
to misfolded proteins.
High Ranking Transcriptional Regulators
Could Have Pleiotropic Effects on AD
A final set of high-ranking genes was broadly involved in
transcriptional regulation. The high-ranking amygdala gene
EDF1 encodes a factor that acts as a transcriptional coactivator
of peroxisome proliferator-activated receptor-gamma (PPARγ)
(Figure 6G and Table 2). PPARγ has multiple functions,
including regulating metabolism (Pipatpiboon et al., 2012),
supporting vascular endothelial cells (Cazzaniga et al., 2018),
and promoting BDNF expression (d’Angelo et al., 2019). It has
been hypothesized that PPARγ counteracts insulin resistance
and metabolic dysfunction in AD (Hoyer and Lannert, 1999;
Pipatpiboon et al., 2012). It potentially also plays a role in
modifying extracellular Aβ levels by facilitating increased uptake
of Aβ by neurons and glia (Mandrekar-Colucci et al., 2012).
PPARγ also downregulates the pro-inflammatory mechanisms of
AD pathology (Combs et al., 2000; Govindarajulu et al., 2018).
Common variants within the EDF1 gene could have pleiotropic
effects on cellular function through the regulation of PPARγ.
The hippocampal gene HDAC3 encodes a histone deacetylase
enzyme that epigenetically regulates gene expression (McQuown
and Wood, 2011; Nott et al., 2016) (Figure 6H and Table 1).
Extra-synaptic glutamate signaling drives pro-apoptotic gene
expression, in part through the FOXO transcription factor,
which is upregulated by extra-synaptic signaling (Parsons and
Raymond, 2014). FOXO forms a complex with HDAC3, the
protein product of HDAC3, and suppresses gene transcription
(Nott et al., 2016). Thus, common variants in HDAC3
could influence pro-apoptotic gene expression, exacerbating
hippocampal atrophy.
HDAC3, and other members of the HDAC family, also
negatively regulate long-term memory formation (McQuown
and Wood, 2011; Zhu et al., 2017), via the “molecular brake
pad hypothesis” (McQuown and Wood, 2011). The molecular
brake pad hypothesis posits that the tight binding of HDACs to
the promoters of genes that drive memory formation requires
high-levels of activity-dependent signaling to dissociate them
and enable protein synthesis-dependent long-term memory
formation (McQuown and Wood, 2011). Notably, HDAC3 has
also been found to affect dendritic spine density, amyloid burden,
microglial activation, and spatial memory in the APP/PS1
AD mouse model (Zhu et al., 2017). Furthermore, in the
3xTG-AD mouse model, inhibition of HDAC3 reversed AD-
related pathologies (Janczura et al., 2018), and in cultured
rat hippocampal neurons, inhibition of HDAC3 reversed
Aβ-induced plasticity deficits (Krishna et al., 2016). Interestingly,
another histone deacetylase inhibitor, HDAC2, is emerging as a
potential drug target in AD (Choubey and Jeyakanthan, 2018).
Together, these results suggest pleiotropic roles for HDAC3 as a
gene influencing hippocampal atrophy in AD.
In summary, the genes prioritized by our integrative method
are robustly related to AD by prior research and have clear
pathways connecting them to neuron death, and therefore, to the
imaging signals of low HV and AV.
The present study was potentially limited by a number of
important factors. First, by treating HV and AV independently
as quantitative traits, we potentially miss important population
substructure (e.g., discrete patient subgroups with extreme
neuropathology). While we do not see obvious subgroups in the
HV/AV data (Figure 2), it is possible that by paring MRI with
other phenotypic measures, such groups could appear. Future
multi-trait analyses could have greater power to detect risk factors
for patient subgroups, such as those that have been detected in
gene expression data (Mukherjee et al., 2020). In particular, with
emerging longitudinal data, it may become possible to identify
subgroups that have distinct disease trajectories. Second, we
have applied an NGR method that has been extensively tested,
applied, and validated (Guan et al., 2010; Gorenshteyn et al.,
2015; Goya et al., 2015; Greene et al., 2015; Krishnan et al.,
2016; Song et al., 2016; Yao et al., 2018; Tyler et al., 2019).
However, NGR methods are under active development, with new
variants using different machine learning strategies or molecular
networks. Future work can benchmark different NGR strategies
prior to our integrative prioritization to identify the most robust
combination of molecular network and learning algorithm for
AD GWAS. Third, the present study focused on the genomic data
alone. Neither the meta-GWAS or the ADNI-1 data in this study
have gene expression for the study participants. However, gene
expression data from patients with AD exist in other data sets,
such as the Religious Orders Study (Bennett et al., 2012). Future
work could integrate gene expression data into a prioritization
pipeline, which has been done in other fields, such as cancer
(Ritchie et al., 2013). Finally, we have not validated any of our
gene candidates experimentally, and the proposed mechanisms
for our highly ranked genes are speculative.
Frontiers in Genetics | www.frontiersin.org 13 April 2021 | Volume 12 | Article 625246
fgene-12-625246 March 30, 2021 Time: 17:37 # 14
Brabec et al. System-Level Analysis of AD
Despite the above limitations, however, the integrative
approach we have taken has strongly implicated cytoskeletal
dynamics, ER stress, and transcriptional dysregulation as major
cellular processes driving neural atrophy. While it is beyond the
scope of the present study to validate any of our candidates,
by highlighting specific cellular processes and genes taking part
in those processes, we can design robust in vivo and in vitro
experiments to test them. For example, recent results in cultured
neurons implicate impaired dendritic dynamics as a hallmark of
AD (Froula et al., 2018; Boros et al., 2019; Henderson et al., 2019;
Walker and Herskowitz, 2020; Walker et al., 2021). Such culture
systems could be used for follow up experiments in which our
candidate genes could feasibly be tested at scale.
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